ALBIREO PHARMA, INC.
DelistedCIK 1322505fmd_18M4A8800XD614PP9JM5V6WNR0Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2004 to Sep 30, 2022, 55 periods
| Line item | FY2014 | FY2015 | FY2015 | FY2016 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 0 | 13 | 10 | 8 | 41 |
| Net interest income | – | – | (2) | – | (1) | 0 | (5) | (5) | – | – |
| Cost of revenue | – | – | – | – | – | – | – | – | – | 1 |
| Gross profit | – | – | – | – | – | – | – | – | 8 | 39 |
| Research and development | 14 | 13 | – | – | 8 | 13 | 32 | 46 | 77 | 83 |
| Selling, general and administrative | – | – | – | – | – | – | – | – | 42 | 70 |
| Total operating expenses | 19 | 20 | – | – | 24 | 25 | 51 | 71 | 105 | 163 |
| Operating income | – | – | (5) | – | (12) | (25) | (38) | (61) | (96) | (123) |
| Interest and investment income | 0 | 0 | – | 0 | – | – | – | – | – | – |
| Other non-operating income (expense) | – | – | (0) | – | (3) | 0 | (3) | 4 | – | – |
| Income before taxes | (14) | – | (7) | – | (16) | (24) | (46) | (63) | (108) | (34) |
| Income tax expense | 0 | 0 | – | – | 0 | 0 | 0 | – | – | – |
| Net income from continuing operations | (14) | – | (7) | – | (16) | (24) | (46) | – | – | – |
| Net income | (14) | (19) | – | – | (16) | (24) | (46) | (63) | (108) | (34) |
| Net income to common shareholders | – | – | – | – | – | – | – | (63) | (108) | (34) |